The Pharmacology of Lymphocytes pp 587-610

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 85) | Cite as

Future Prospects for Drug Design of Lymphocyte Modulators

  • J. Drews
  • W. Haas


There are well-established procedures for the design and presentation of scientific reviews. Unfortunately, all of the conventions and rules developed in this context are quite useless when it comes to writing a scientific preview, or to put it more bluntly, to predicting the future of a given area of research. By its very nature, scientific progress is unpredictable. We are entitled to assume that progress will continue in the future as it has in the past, but we know nothing about its quality, and we can only guess at which point in time a particular scientific question can be answered. The task of designing future therapy in any area of pharmacology is therefore a rather futile one, and is more likely to contribute to the amusement of future generations of scientists than to the enlightenment of the present one. However, drug therapy is not only a matter of research, but also a matter of applying the results of basic research to a particular therapeutic purpose, a process which we may call development.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adelman NE, Watling DL, McDevitt HO (1983) Treatment of (NZB x NZW) F1 disease with anti-IA monoclonal antibodies. J Exp Med 158: 1350–1355PubMedCrossRefGoogle Scholar
  2. Allum WH, Macdonald F, Fielding JW (1986) Monoclonal antibodies in the diagnosis and treatment of malignant conditions. Surg Annu 18:41–64PubMedGoogle Scholar
  3. Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier JW (1986) Phase I evaluation of a recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 4:1380–1391PubMedGoogle Scholar
  4. Avella J, Binder HJ, Madsen JE, Askenase PhW (1978) Effect of histamine H2receptor antagonists on delayed hypersensitivity. Lancet 1:624–626PubMedCrossRefGoogle Scholar
  5. Baldwin RW, Byers VS (1985) Monoclonal antibodies for cancer detection and therapy. Academic, LondonGoogle Scholar
  6. Basciano L-AK, Berenstein EH, Kmak L, Siraganian RP (1986) Monoclonal antibodies that inhibit IgE binding. J Biol Chem 261:11823–11831PubMedGoogle Scholar
  7. Benjamin RJ, Waldmann H (1986) Induction of tolerance by monoclonal antibody therapy. Nature 320:449–451PubMedCrossRefGoogle Scholar
  8. Benjamin RH, Cobbolt SP, Clark MR, Waldmann H (1986) Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 163:1539–1552PubMedCrossRefGoogle Scholar
  9. Bennett J, Zloty P, McKneally M (1982) Cimetidine blocks the development of tumor-induced suppressor T-cell activity. Int J Immunopharmacol 4:280CrossRefGoogle Scholar
  10. Berridge MJ, Irvine RF (1984) Inositol triphosphate, a novel second messenger in cellular signal-transduction. Nature 312:315–321PubMedCrossRefGoogle Scholar
  11. Biddison WE, Rao PE, Talle MA, Goldstein G, Shaw S (1984) Possible involvement of the T4 molecules in T cell recognition of class II HLA antigens: evidence from studies of CTL-target cell binding. J Exp Med 159:783–797PubMedCrossRefGoogle Scholar
  12. Bijsterbosch MK, Meade ChJ, Turner GA, Klaus GGB (1985) B lymphocyte receptors and polyphosphoinositide degradation. Cell 41:999–1006PubMedCrossRefGoogle Scholar
  13. Blackwell GJ, Carnuccio R, DiRosa M, Flower RJ, Parente L, Persico P (1980) Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 287:147–149PubMedCrossRefGoogle Scholar
  14. Boitard C, Mishic S, Serrurier P, Butcher GW, Larkins AP, McDevitt HO (1985) In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility gene products. Proc Natl Acad Sci USA 82:6627–6632PubMedCrossRefGoogle Scholar
  15. Borst J, Alexander S, Elder J, Terhorst C (1983) The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins. J Biol Chem 258:5135–5141PubMedGoogle Scholar
  16. Borst J, Coligan JE, Oettgen H, Pessano S, Malin R, Terhorst C (1984) The S and s-chains of the human T3/T-cell receptor complex are distinct polypeptides. Nature 312:455–458PubMedCrossRefGoogle Scholar
  17. Bortin MM (1986) Allogeneic bone marrow transplantation in leukemia patients. Curr Probt Cancer 10:1–52CrossRefGoogle Scholar
  18. Brenner MB, McLean J, Dialynas DP, et al. (1986) Identification of a putative second T cell receptor. Nature 322:145–149PubMedCrossRefGoogle Scholar
  19. Brostoff SW, Mason DW (1984) Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol 133:1938–1943PubMedGoogle Scholar
  20. Cahill J, Hopper KE (1984) Immunoregutation by macrophages III. Prostaglandin E suppresses lymphocyte activation but not macrophage effector function during Salmonella enteritidis infection. Int J Immunopharmacol 6:9–17PubMedCrossRefGoogle Scholar
  21. Cambier JC, Monroe JG, Coggeshali KM, et al. (1985) The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin. Immunol Today 6:218–222CrossRefGoogle Scholar
  22. Cantrell MA, Anderson D, Cerretti DP, et al. (1985) Cloning sequence and expression of a human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci USA 82:6250–6254PubMedCrossRefGoogle Scholar
  23. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Bach JF (1985) The restricted immune response to the murine monoclonal OKT3 antibody. Transplant Proc 17:558–559Google Scholar
  24. Chatenoud L, Jonker M, Villemain G, Goldstein G, Bach JF (1986) The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 232:1406–1408PubMedCrossRefGoogle Scholar
  25. Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP, Lefrancier PL (1982) Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 35:417–424PubMedGoogle Scholar
  26. Cheever MA, Greenberg PD, Fefer A (1984) Potential for specific cancer therapy with immune T lymphocytes. J Biol Response Mod 3:113–127PubMedGoogle Scholar
  27. Chiao JW, Heil M, Arlin Z, Lutton JD, Choi JS, Leung K (1986) Suppression of lymphocyte activation and functions by a leukemia cell-derived inhibitor. Proc Natl Acad Sci USA 83:3432–3436PubMedCrossRefGoogle Scholar
  28. Clark EA, Ledbetter JA (1986) Amplification of the immune response by agonistic antibodies. Immunol Today 7:267–270CrossRefGoogle Scholar
  29. Cloix JF, Colard O, Rothut B, Russo-Marie F (1983) Characterization and partial purification of “renocortins”: two polypeptides formed in renal cells causing the anti-phospholipase-like action of glucocorticoids. Br J Pharmacol 79:313–321PubMedGoogle Scholar
  30. Cobbolt SP, Martin G, Ain S, Waldmann H (1986) Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323:164–166CrossRefGoogle Scholar
  31. Cohen FE, Kosen PA, Kuntz ID, Eppstein LB, Ciardelli TL, Smith KA (1986) Structure-activity studies of interleukin-2. Science 234:349–352PubMedCrossRefGoogle Scholar
  32. De Simone C, Meli D, Sbricoli M, Rebuzzi E, Koverech A (1982) In vitro effect of inosiplex on T lymphocytes. J Immunopharmacol 4:139–152PubMedGoogle Scholar
  33. Dembic Z, Haas W, Weiss S, McCurbey J, Kiefer H, Boehmer H, Steinmetz M (1986) Transfer of specificity by murine a and ß T cell receptor genes. Nature 320:232–238PubMedCrossRefGoogle Scholar
  34. Dijk H van, Rademaker PM, Kerkhofs JP, Willers JMN (1980) Histamine 2-receptor-mediated immunomodulation in the mouse. II. Immunomodulation by the H2 antagonist metiamide. Int J Immunopharmacol 2:345–352PubMedCrossRefGoogle Scholar
  35. Dinarello CA (1986) Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). In: Cruse M, Lewis RE (eds) The Year in Immunology, vol 2. Karger, Basel, pp 68–89Google Scholar
  36. Donahue RE, Wang EA, Stone DK, Kamen R, Wong GG, Sehgal PK, Nathan DG, Clark SC (1986) Stimulation of hematopoiesis in primates by continuous infusion of recombinant human GM-CFS. Nature 321:872–875PubMedCrossRefGoogle Scholar
  37. Drews J (1984) The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections. Infection 13:241–250CrossRefGoogle Scholar
  38. Drews J (1986) Immunpharmakologie, Grundlagen, Perspektiven. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  39. Duff G (1985) Many roles for interleukin-1. Nature 313:352–353PubMedCrossRefGoogle Scholar
  40. Duff GW, Durum SK (1983) The pyrogenic and mitogenic actions of interleukin-1 are related. Nature 304:449–451PubMedCrossRefGoogle Scholar
  41. Ferrara JLM, Marion A, McIntyre JF, Murphy GF, Burakoff SJ (1986) Amelioration of acute graft versus host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin-2 receptor antibody. J Immunol 137:1874–1877PubMedGoogle Scholar
  42. Fraser-Smith EB, Matthews TR (1981) Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida ablicans. Infect Immun 34:676–683PubMedGoogle Scholar
  43. Fraser-Smith EB, Eppstein DA, Larsen MA, Matthews TR (1983) Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection. Infect Immun 39:172–178PubMedGoogle Scholar
  44. Geha RS, Helm B, Gould H (1985) Inhibition of the Prausnitz-Kästner reaction by an immunoglobulin E-chain synthesized by E. coli. Nature 315:577–578PubMedCrossRefGoogle Scholar
  45. Gemsa D, Deimann W, Bärlin E, Seitz M, Leser HG (1982) Die Rolle von Prostaglandinen aus Makrophagen bei Regulation and Suppression der Immunantwort. Allergologie 5:142–150Google Scholar
  46. Gifford RRM, Ferguson RM, Voss BV (1981) Cimetidine reduction of tumor formation in mice. Lancet 1:638–639PubMedCrossRefGoogle Scholar
  47. Goldstein D, Laszlo J (1986) Perspectives in cancer research: interferon therapy in cancer: from imagination to interferon. Rev Cancer Res 46:4315–4329Google Scholar
  48. Goldstein G, Schindler J, Sheahan M, Barnes L, Tsai H (1985) Orthoclone OKT3 treatment of acute renal allograft rejection. Transplant Proc 17:129–130Google Scholar
  49. Goodman MG (1984) Inductive and differentiative signals delivered by C8-substituted guanine ribonucleosides. Immunol Today 5:319–324CrossRefGoogle Scholar
  50. Goodwin JS, Ceuppens J (1983) Regulation of the immune response by prostaglandins. J Clin Immunol 3:295–315PubMedCrossRefGoogle Scholar
  51. Goronzy J, Weyand CM, Fathman CG (1986) Long-term humoral unresponsiveness in vivo induced by treatment with monoclonal antibody against L3T4. J Exp Med 164:911–925PubMedCrossRefGoogle Scholar
  52. Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt I +2_ T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161:1122–1134PubMedCrossRefGoogle Scholar
  53. Greenstein JL, Malissen B, Burakoff SJ (1985) Role of L3T4 in antigen-driven activation of a class I-specific T cell hybridoma. J Exp Med 162:369–374PubMedCrossRefGoogle Scholar
  54. Haas W, von Boehmer J (1985) T cell proliferation and differentiation. In: Weissman I (ed) Leukemia. Springer, Berlin Heidelberg New York, pp 21–30CrossRefGoogle Scholar
  55. Hardt C, Röllinghoff M, Pfizenmaier K, Mosmann H, Wagner H (1981) Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin-2 inhibitor in vivo. J Exp Med 154:262–274PubMedCrossRefGoogle Scholar
  56. Hersey P, Bindon C, Bradley M, Hasic E (1984) Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in poke-weed mitogen stimulated cultures of B and T cells. Int J Immunopharmacol 6:321–328PubMedCrossRefGoogle Scholar
  57. Hess AD, Horwitz L, Beschorner WE, Santos GW (1985) Development of graft versus host disease like syndrome in cyclosporine treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal antiIa specificity including autoreactivity. J Exp Med 161:718–730PubMedCrossRefGoogle Scholar
  58. Hess AD, Colombani PM, Esa AH (1986) Cyclosporine and the immune response: basic aspects. Crit Rev Immunol 6:123–149PubMedGoogle Scholar
  59. Hirata F, Schiffmann E, Venkatasubramamian K, Salomon D, Axelrod J (1980) A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 77:2533–2536PubMedCrossRefGoogle Scholar
  60. Hirschhorn R (1983) Metabolic defects and immunodeficiency disorders. N Eng J Med 308:714–716CrossRefGoogle Scholar
  61. Honda M, Chan Ch, Shevach EM (1985) Characterization and partial purification of a specific interleukin-2 inhibitor. J Immunol 135:1834–1839PubMedGoogle Scholar
  62. Hoyer M, Meinecke T, Lewis W, Zwilling B, Rinehart J (1986) Characterization and modulation of human lymphokine (interleukin-2) activated killer cell induction. Cancer Res 46:2834–2838PubMedGoogle Scholar
  63. Isakov N, Scholz W, Altman A (1986) Signal transduction and intracellular events in T lymphocyte activation. Immunol Today 7:271–277CrossRefGoogle Scholar
  64. Ishizaka K, Yodoi J, Suemura M, Hirashima M (1983) Isotype specific regulation of the IgE response by IgE binding factors. Immunol Today 4:192–194CrossRefGoogle Scholar
  65. Ito M, Bandyopadhyay S, Matsumoto-Kobayashi M, Clark SC, Miller D, Starr SE (1986) Interleukin-2 enhances natural killing of varicella-zoster virus infected targets. Clin Exp Immunol 65:182–189PubMedGoogle Scholar
  66. Itoh K, Tilden AB, Kumagai K, Balch ChM (1985) Leu-11 + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin-2 (rIL-2)-induced activated killer (AK) cells. J Immunol 134:802–807PubMedGoogle Scholar
  67. Iwata M, Huff TF, Ishizaka K (1984) Modulation of the biologic activities of IgE-binding factor. V. The role of glycosylation-enhancing factor and glycosylation-inhibiting factor determining the nature of IgE-binding factors. J Immunol 132:1286–1293PubMedGoogle Scholar
  68. Jansen J, Falkenberg JHF, Stepan DE, LeBien TW (1984) Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Semin Hematol 21:164–181PubMedGoogle Scholar
  69. Jardieu P, Uede T, Ishizaka K (1984) IgE-binding factor from mouse T lymphocytes. III. Role of antigen-specific suppressor T cells in the formation of IgE-suppressive factor. J Immunol 133:3266–3273PubMedGoogle Scholar
  70. Jesdinsky HJ (1983) Cooperative group of additional immunoglobulin therapy in severe bacterial infections: multicenter randomized controlled trial on the efficacy of additional immunoglobulin therapy in cases of diffuse fibrino-purulent peritonitis — study design. Klin Wochenschr 61:445–450CrossRefGoogle Scholar
  71. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525PubMedCrossRefGoogle Scholar
  72. Jorizzo JL, Sams MW, Jegasothy BV, Olansky AJ (1980) Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 92 (1):192–195PubMedGoogle Scholar
  73. Katz DH (1984) Regulation of the IgE system: experimental and clinical aspects. Allergy 39:81–106PubMedCrossRefGoogle Scholar
  74. Kawano M, Iwato K, Kuramoto A (1985) Identification and characterization of a B cell growth inhibitory factor (BIF) on BCGF-dependent B cell proliferation. J Immunol 134:375–381PubMedGoogle Scholar
  75. Kawasaki ES, Ladner MB, Wang AM, et al. (1985) Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). Science 230:291–296PubMedCrossRefGoogle Scholar
  76. Kelley VE, Noar D, Tarcic N, Gaulton GN, Strom TB (1986) Anti-interleukin-2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol 137:2122–2124PubMedGoogle Scholar
  77. Kingston AE, Kay JE, Ivanyi J (1985) The effects of prostaglandin E and I analogues on lymphocyte stimulation. Int J Immunopharmacol 7:57–64PubMedCrossRefGoogle Scholar
  78. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB (1985) Administration of anti-interleukin-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 162:358–362PubMedCrossRefGoogle Scholar
  79. Konrad MW, Bradley EC (1986) The pharmacokinetics of a recombinant IL-2 muteine given by five routes in a number of phase I trials (abstract). Proc Am Soc Clin Oncol 5:235Google Scholar
  80. Kramer M, Koszinowski U (1982) T cell-specific suppressor factor(s) with regulatory influence on interleukin-2 production and function. J Immunol 128:784–790PubMedGoogle Scholar
  81. Krönke M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC (1984) Cyclosporine A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 81:5214–5218PubMedCrossRefGoogle Scholar
  82. Kuff EL, Mietz JA, Troustine ML, Moore KW, Martens CL (1986) cDNA clones encoding murine IgE-binding factors represent multiple structural variants of intracisternal A-particle genes. Proc Natl Acad Sci USA 83:6583–6587PubMedCrossRefGoogle Scholar
  83. Kuo LM, Robb RJ (1986) Structure function relationships for the IL-2 receptor system. 1. Localization of a receptor binding site on IL-2. J Immunol 137:1538–1543PubMedGoogle Scholar
  84. Kuo LM, Rusk CM, Robb RJ (1986) Structure function relationship for the IL-2 receptor system. II. Localization of an IL-2 binding site on high and low affinity receptors. J Immunol 137:1544–1551PubMedGoogle Scholar
  85. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB (1986) Therapy with monoclonal antibody to interleukin-2 receptors spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 83:2624–2627PubMedCrossRefGoogle Scholar
  86. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD/6 (Leu 11), Leu 19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480–4485PubMedGoogle Scholar
  87. Like AA, Biron CA, Weringer EJ, Byman K, Sroczynski E, Guberski DL (1986) Prevention of diabetes in biobreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med 164:1145–1159PubMedCrossRefGoogle Scholar
  88. Liu FT, Albrand K, Mendel E, Kulczycki, Orida NK (1985) Identification of an IgE-binding protein by molecular cloning. Proc Natl Acad Sci USA 82:4100–4104PubMedCrossRefGoogle Scholar
  89. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan Y-CE, Collier K, Semionow R, Chua AO, Mizel SB (1984) Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312:458–462PubMedCrossRefGoogle Scholar
  90. Lou CY, Wang EY, Li D, Budz-Tymkewycz S, Visconti V, Ishague A (1985) Mechanism of action of a suppressor-activating factor (SAF) produced by a human T cell line. J Immunol 134:3155–3162Google Scholar
  91. MacDonald HR, Glasebrook AL, Bron C, Kelso A, Cerottini JC (1982) Clonal heterogeneity in the functional requirement for Lyt-2/3 molecules on cytolytic T lymphocytes (CTL): possible implications for the affinity of CTL antigen receptors. Immunol Rev 68:89–115PubMedCrossRefGoogle Scholar
  92. Marceletti JF, Katz DH (1984) FcRe+ lymphocytes and regulation of the IgE antibody system. IV Delineation of target cells and mechanism of action of SFA and EFA in inhibiting in vitro induction of FcRe expression. J Immunol 133:2845–2851Google Scholar
  93. Marrack P, Endrew R, Shimonkevitz R, Zlotnik A, Dialynas D, Fitch F, Kappler J (1983) The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product. J Exp Med 158:1077–1091PubMedCrossRefGoogle Scholar
  94. Medoff JR, Clack VD, Roche JK (1986) Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. J Immunol 137:2057–2064PubMedGoogle Scholar
  95. Merluzzi VJ, Last-Barney K (1985) Potential use of human interleukin-2 as an adjunct for the therapy of neoplasia, immunodeficiency and infectious disease. Int J Immunopharmacol 7:31–39PubMedCrossRefGoogle Scholar
  96. Metcalf D (1985) The granulocyte-macrophage colony-stimulating factors. Science 229:16–22PubMedCrossRefGoogle Scholar
  97. Moingeon M, Ythier A, Goubin G, Faure F, Nowill A, Delmon L, Rainaud M, Forestier F, Daffos F, Bohuon C, Hercend T (1986) A unique T cell receptor complex expressed on human fetal lymphocytes displaying natural killer like activity. Nature 323:638–640PubMedCrossRefGoogle Scholar
  98. Morley J (1979) Prostaglandins and chronic inflammation. In: Rainsford KD, Ford-Hutchinson AW (eds) Prostaglandins and inflammation. Birkhäuser, Basel, pp 133–141CrossRefGoogle Scholar
  99. Morley J (ed) (1982) Bronchial hyperreactivity. Academic, LondonGoogle Scholar
  100. Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229:1202–1207PubMedCrossRefGoogle Scholar
  101. Nakamura T, Miyasaka N, Pope RM, Talal N, Russel IJ (1983) Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases. Clin Exp Immunol 52:67–74PubMedGoogle Scholar
  102. Nathan CF, Murray HW, Wiebe ME, Rubin BY (1983) Identification of interferon-y as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158:670–689PubMedCrossRefGoogle Scholar
  103. Neuberger MS, Williams GT, Fox RO (1984) Recombinant antibodies possessing novel effector functions. Nature 312:604–608PubMedCrossRefGoogle Scholar
  104. Nicola NA, Begley CG, Metcalf D (1985) Identification of the human analogue of a regulator that induces differentiation in murine leukemic cells. Nature 314:625–628PubMedCrossRefGoogle Scholar
  105. Nishizuka Y (1984) Turnover of inositol phospholipids and signal transduction. Science 225:1365–1370PubMedCrossRefGoogle Scholar
  106. Nydegger UE (1985) Suppressive and substitutive immunotherapy: an essay with a review of recent literature. Immunol Lett 9:185–190PubMedCrossRefGoogle Scholar
  107. Obert HJ, Brzoska J (1986) Interferon-y in therapy of rheumatoid arthritis. Drug Res 36:1557–1560Google Scholar
  108. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK (1986) There is more than one interleukin-1 Immunol. Today 7:45–56Google Scholar
  109. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-associated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193–1205PubMedCrossRefGoogle Scholar
  110. Ortho Multicenter Tranplant Group (1985) A randomized clinical trial OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342CrossRefGoogle Scholar
  111. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin activated lymphocytes for leukemia and lymphoma. Blood 68:938–948PubMedGoogle Scholar
  112. Pasino M, Bellone M, Cornaglia P, Tonini GP, Massimo L (1982) Methisoprinol effect on enriched B and T lymphocyte populations stimulated with phytohemagglutinin. J Immunopharmacol 4:101–108PubMedCrossRefGoogle Scholar
  113. Pestka S (1986) Interferons from 1981–1986. Methods Enzymol 119:3–14PubMedCrossRefGoogle Scholar
  114. Phillips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814–825PubMedCrossRefGoogle Scholar
  115. Pizza G, Severini G, Menniti D, DeVinci C, Corrado F (1984) Tumor regressions after intralesional injection of interleukin-2 (IL-2) in bladder cancer: preliminary report. Int J Cancer 34:359–367PubMedCrossRefGoogle Scholar
  116. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS (1986) Biological and immunological characterization of ATG and ALG. Blood 68:712–719PubMedGoogle Scholar
  117. Rappaport RS, Dodge GR (1982) Prostaglandin E inhibits the production of human interleukin-2. J Exp Med 155:943–948PubMedCrossRefGoogle Scholar
  118. Rosenberg SA (1984) Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 68:233–255PubMedGoogle Scholar
  119. Rosenberg SA (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595–603PubMedGoogle Scholar
  120. Rosenberg SA, Lotze MT, Muul LM, et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492PubMedCrossRefGoogle Scholar
  121. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321PubMedCrossRefGoogle Scholar
  122. Rothhut B, Russo-Marie F, Wood J, DiRosa M, Flower RJ (1983) Further characterization of the glucocorticoid-induced antiphospholipase protein “Renocortin”. Biochem Biophys Res Commun 117:878–884PubMedCrossRefGoogle Scholar
  123. Schulte-Wissermann H, Schofer O, Dinkel E (1982) Die Therapie mit y-Globulin. Struktur, Wirkungsweise and Einsatzmöglichkeiten intravenös applizierbarer y-Globulinpräparate. Immun Infekt 10:98–109PubMedGoogle Scholar
  124. Sell S, Reisfeld RA (1985) Monoclonal antibodies in cancer. Human Press, Clifton, New JerseyCrossRefGoogle Scholar
  125. Shirakawa F, Tanaka Y, Oda S, Chiba S, Suzuki H, Eto S, Yamashita U (1986) Immuno-suppressive factors from adult T cell leukemia cells. Cancer Res 46:4458–4462PubMedGoogle Scholar
  126. Shu-Mei Liang, Thatcher DR, Chi-Ming Liang, Allet B (1986) Studies of structure-activity relationship of human interleukin-2. J Immunol 261:334–337Google Scholar
  127. Sidiropoulos D, Böhme U, von Muralt G, Morell A, Barandun S (1981) Immunglobulin-substitution bei der Behandlung der neonatalen Sepsis. Schweiz Med Wochenschr 111:1649–1655PubMedGoogle Scholar
  128. Sondel MP, Hank JA, Kohler PC, Chen BP, Minkoff DZ, Molenda JA (1986) Destruction of autologous human lymphocytes by interleukin-2 activated cytotoxic cells. J Immunol 137:502–511PubMedGoogle Scholar
  129. Souza LM, Boone TC, Gabrilove A, et al. (1986) Recombinant human granulocyte colony- stimulating factor: effects on normal and leukemic myeloid cells. Science 232:61–65PubMedCrossRefGoogle Scholar
  130. Steinman L, Rosenbaum J, Sriram S, McDevitt HO (1981) In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA 78:7111–7114PubMedCrossRefGoogle Scholar
  131. Stevenson GT (1986) The prospect for treating cancer with antibody. Sci Prog 70:505–519PubMedGoogle Scholar
  132. Storb R, Deeg HJ, Whitehead J, et al. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Eng J Med 314:729–735CrossRefGoogle Scholar
  133. Suzuki S, Huchet R (1981) Mechanism of histamine-induced inhibition of lymphocyte response to mitogens in mice. Cell Immunol 62:396–405PubMedCrossRefGoogle Scholar
  134. Swain SL (1983) T cell subsets and the recognition of MHC class. Immunol Rev 74:129–142PubMedCrossRefGoogle Scholar
  135. Talmadge JE, Lenz BF, Klabonsky R, Simon R, Rigg C, Guo S, Oldham RK, Fidler IJ (1986) Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res 46:1160–1163PubMedGoogle Scholar
  136. Tandom P, Utsugi T, Sone S (1986) Lack of production of interleukin-1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide. Cancer Res 46:5039–5044Google Scholar
  137. Thurman GB, Maluish AE, Rossio JL et al. (1986) Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations. J Biol Response Mod 5:85–107PubMedGoogle Scholar
  138. Traber R, Kuhn M, Rilegger A, Lichti H, Loosli HR, von Wartburg A (1977a) Die Struktur von Cyclosporin C. Helv Chim Acta 60:1247–1255CrossRefGoogle Scholar
  139. Traber R, Kuhn M, Loosli HR, Pache W, von Wartburg A (1977b) Neue Cyclopeptide aus Trichoderma polysporum (Link ex Pers.) Rifai: die Cyclosporine B, D and E. Helv Chim Acta 60:1568–1578CrossRefGoogle Scholar
  140. Trang LE (1980) Prostaglandins and inflammation. Semin Arthritis Rheum 9:153–159PubMedCrossRefGoogle Scholar
  141. Uede T, Hirata F, Hirashima M, Ishizaka K (1983) Modulation of the biologic activities of IgE-binding factors. I. Identification of glycosylation-inhibiting factor as a fragment of lipomodulin. J Immunol 130:878–884PubMedGoogle Scholar
  142. Uede T, Huff TF, Ishizaka K (1984) Suppression of IgE synthesis in mouse plasma cells and B cells by rat IgE-suppressive factor. J Immunol 133:803–808PubMedGoogle Scholar
  143. Waldor MK, Sriram S, McDevitt HO, Steinman L (1983) In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA 80:2713–2717PubMedCrossRefGoogle Scholar
  144. Waldor MK, Hardy RR, Hayakawa K, Steinman L, Herzenberg LA, Herzenberg LA (1984) Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc Natl Acad Sci USA 81:2855–2858PubMedCrossRefGoogle Scholar
  145. Waldor MK, Sriram S, Hardy R, Herzenberg LA, Herzenberg LA, Lanier L, Lim M, Steinman L (1985) Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T cell subset marker. Science 227:415–419PubMedCrossRefGoogle Scholar
  146. Walker C, Kristensen F, Bettens F, deWeck AL (1983) Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin-2 production. J Immunol 130:1770–1773PubMedGoogle Scholar
  147. Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Pingchang Chow E, Browning JL, Ramachandran KL, Pepinsky RB (1986) Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320:77–81PubMedCrossRefGoogle Scholar
  148. Wang A, Shi-Da Lu, Mark DF (1984) Site specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224:1431–1433PubMedCrossRefGoogle Scholar
  149. Ward JR, Samuelson CO (1982) Nonsteroidal antiinflammatory drugs. In: Isselbacher KJ (ed) Update II. Harrison’s principles of internal medicine. McGraw Hill, New York, pp 91–110Google Scholar
  150. Weigent DA, Hoeprich PD, Bost KL, Brunck TK, Reiher WE, Blalock JE (1986) The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptor. Biochem Biophys Res Commun 139:367–374PubMedCrossRefGoogle Scholar
  151. Whiteside TL, Miescher S, Hürlimann J, Moretta L, von Fliedner V (1986a) Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 37:803–811CrossRefGoogle Scholar
  152. Whiteside TL, Miescher S, MacDonald HR, von Fliedner V (1986b) Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 90:221–233CrossRefGoogle Scholar
  153. Wofsy D, Seaman WE (1985) Successful treatment of autoimmunity in NZB/NZW F 1 mice with monoclonal antibody L3T4. J Exp Med 161:378–391PubMedCrossRefGoogle Scholar
  154. Wofsy D, Mayes DC, Woodcook J, Seaman WE (1985) Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol 135:1698–1703PubMedGoogle Scholar
  155. Yanagi Y, Caccia N, Kronenberg M, et al. (1985) Gene rearrangement in cells with natural killer activity and expression of the ß-chain of the T cell antigen receptor. Nature 314:631–633PubMedCrossRefGoogle Scholar
  156. Yodoi J, Hirashima M, Ishizaka K (1982) Regulatory role of IgE-binding factors from rat T lymphocytes. V. Carbohydrate moieties in IgE-potentiating factors and IgE-suppressive factor. J Immunol 128:289–295PubMedGoogle Scholar
  157. Young LS (1985) Monoclonal antibodies: technology and application to gram-negative infections. Infection 13:224–228CrossRefGoogle Scholar
  158. Yu-Chung Yang, Ciarletta AB, Temple PA, Chung MP, Kovacic S, Witek-Giannotti JAS, Leary AC, Kriz R, Clark SC (1986) Human IL-3 (multi CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47:3–10PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. Drews
  • W. Haas

There are no affiliations available

Personalised recommendations